Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma

NCT01206296 is registered in ClinicalTrials.gov with Medstar Health Research Institute as lead sponsor.

NCT NCT01206296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01206296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
Lead sponsor
Medstar Health Research Institute
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2010
Completion date
February 28, 2014
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma